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Pharmacokinetic and Pharmacodynamic
Comparison of Once-Daily Efavirenz (400 mg vs.
600 mg) in Treatment-Na€ıve HIV-Infected
Patients: Results of the ENCORE1 Study
L Dickinson1, J Amin2, L Else1, M Boffito3, D Egan1, A Owen1, S Khoo1, D Back1, C Orrell4, A Clarke5,
M Losso6, P Phanuphak5, D Carey2, DA Cooper2, S Emery2 and
R Puls2, on behalf of the ENCORE1 Study Group
Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in treatment-na€ıve patients. We evaluated
EFV400 and EFV600 pharmacokinetics (NONMEM v. 7.2), assessing patient demographics and genetic polymorphisms (CYP2B6, CYP2A6,
CYP3A4, NR1I3) as covariates and explored relationships with efficacy (plasma HIV-RNA (pVL) <200 copies/mL) and safety outcomes at 48
weeks in 606 randomized ENCORE1 patients (female5 32%, African5 37%, Asian5 33%; EFV4005 311, EFV6005 295). CYP2B6
516G>T/983T>C/CYP2A6*9B/*17 and weight were associated with efavirenz CL/F. Exposure was significantly lower for EFV400 (geometric
mean ratio, GMR; 90% confidence interval, CI: 0.73 (0.68–0.78)) but 97% (EFV400) and 98% (EFV600) of evaluable pVL was <200 copies/
mL at 48 weeks (P5 0.802). Four of 20 patients with mid-dose concentrations <1.0 mg/L had pVL200 copies/mL (EFV4005 1;
EFV6005 3). Efavirenz exposure was similar between those with and without efavirenz-related side effects (GMR; 90% CI: 0.95 (0.88–
1.02)). HIV suppression was comparable between doses despite significantly lower EFV400 exposure. Comprehensive evaluation of efavirenz
pharmacokinetics/pharmacodynamics revealed important limitations in the accepted threshold concentration.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  ENCORE1 demonstrated noninferior HIV suppression
with EFV400 compared to EFV600 at 48 weeks in treatment-na€ıve patients.  WHAT QUESTION DID THIS STUDY
ADDRESS?  Pharmacokinetic parameters achieved with EFV400 and EFV600 once daily were estimated and patient char-
acteristics and genetic polymorphisms assessed. Differences in pharmacokinetic parameters between doses and in patients
experiencing adverse events were determined and associations at 48 weeks between pVL <200 copies/mL or adverse events
with predicted pharmacokinetic parameters, dose, and polymorphisms were evaluated.  WHAT THIS STUDY ADDS TO
OUR KNOWLEDGE  Significantly lower EFV400 exposure (GMR (90% CI): 0.73 (0.68–0.78)) was not associated with
pVL <200 copies/mL at 48 weeks (EFV400 5 97% vs. EFV600 5 98%; P 5 0.802). Efavirenz-related side effects were
more common with EFV600 than EFV400 but not associated with plasma concentrations. Four of 20 patients with C12
<1.0 mg/L had pVL 200 copies/mL (EFV400 5 1; EFV600 5 3).  HOW THIS MIGHT CHANGE CLINICAL
PHARMACOLOGY AND THERAPEUTICS  Efavirenz dose-reduction retained good virological outcomes and reduced
toxicities and has the potential to cut HIV therapy costs, allowing greater global coverage to patients. These data also chal-
lenge the validity of the widely accepted MEC (1.0 mg/L).
Approximately 10 million people receive antiretrovirals, although
there is disproportionate global access to treatment.1 Current
funds are unlikely to cover a planned scale-up of treatment to 15
million by 2015.2 Exploration of strategies to lower drug costs
may help attain this goal.
Daily therapy including efavirenz (600 mg) with tenofovir
(300 mg) and emtricitabine (200 mg) or lamivudine (300 mg) is rec-
ommended as ﬁrst-line treatment for HIV-infected individuals aged
3 years.3 Historical data suggest similar efﬁcacy of lower efavirenz
doses4 and ENCORE1, a multicenter, double-bind, placebo-
controlled trial comparing reduced dose (400 mg once daily;
EFV400) with standard dose efavirenz (600 mg once daily; EFV600)
in treatment-na€ıve, HIV-infected adults showed that EFV400 was
noninferior to EFV600 at 48 weeks (plasma HIV-RNA (pVL)
<200 copies/mL: 94% vs. 92%, respectively; modiﬁed intent-to-
treat (ITT)).5 Based on 12 million receiving recommended ﬁrst-line
treatment, a reduction to 400 mg efavirenz would save $16 per per-
son in direct drug costs ($192million worldwide per year).6
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Various demographic and genetic factors impact efavirenz dis-
position.7–10 Plasma efavirenz concentrations were associated
with HIV suppression and toxicity when dosed 600 mg once
daily.11–13 ENCORE1 provided an opportunity to examine such
factors in a geographically and genetically diverse group of
patients and to explore relationships between efﬁcacy and safety
outcomes with reduced dose efavirenz. We aimed to determine
pharmacokinetic (PK) parameters of EFV400 and EFV600
and investigate the impact of patient characteristics and
genetics by population PK modeling. Additionally, efavirenz PK/
pharmacodynamic (PD) relationships in patients enrolled in
ENCORE1 at 48 weeks were assessed.
RESULTS
Patients and sampling
Of 630 patients included in the ENCORE1 ITT,5 concentra-
tions (n 5 1,543) were available from 619 individuals (Figure 1).
In total, 3% (n 5 52) of samples were excluded (no recorded
time postdose, time postdose >30 hours, concentration below
assay lower limit of quantiﬁcation (LLQ) or combination
thereof). Overall, 1,491 samples (median (range) 2 (1–9) per
patient; 1–3 occasions per patient) from 606 patients randomized
to EFV400 (n 5 311, 51%) or EFV600 (n 5 295, 49%) were
included. Forty-six patients also participated in the intensive PK
substudy (EFV400, n5 28; EFV600, n 5 18) (Figure 1).
During the study, eight patients (n 5 7 included in the model)
commenced rifampicin-containing tuberculosis (TB) therapy and
switched to open-label efavirenz throughout this phase. Four
patients received rifampicin at weeks 4 or 12 (random sam-
pling): two in EFV400 (one received 600 mg both weeks; one
received 800 mg at week 12) and two in EFV600 (one
received 800 mg both weeks; one remained at 600 mg). Sensi-
tivity analyses compared model-derived population parameters
with and without patients on rifampicin; there were no differ-
ences in estimates and patients were retained in the analysis.
Patient demographics and clinical characteristics are shown
(Table 1).
Genotyping
Blood samples for genotyping were available for 595
patients, 21 of whom were not included in the model (see
Methods). Of 606 patients with PK data, 32 did not have a
genotyping sample (Figure 1). Ampliﬁcation failed in one,
two, and four patients for CYP2B6 15582C>T and
CYP3A4*22, CYP2A6*17 and CYP2A6*9B, respectively. PK
and genetics were available for n 5 574 for CYP2B6
516G>T, CYP2B6 983T>C, NR1I3 540C>T and NR1I3
1089T>C, n 5 573 for CYP2B6 15582C>T and
CYP3A4*22, and n 5 572 and n 5 570 for CYP2A6*17
and CYP2A6*9B, respectively (Figure 1). Genotype frequen-
cies are summarized (Table 1); all were in Hardy–Weinberg
equilibrium and this was also conﬁrmed when stratiﬁed by
ethnicity.
Figure 1 Flow diagram summarizing (a) the data included in the population PK model and (b) genetic data available for analysis. EFV: efavirenz; PK: phar-
macokinetics; WK: week; LLQ: lower limit of qualification; ITT: intent to treat.
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PK modeling
Efavirenz plasma concentrations over time are shown (Figure 2).
A one-compartment model with ﬁrst-order absorption best
described the data, parameterized by apparent oral clearance
(CL/F), apparent volume of distribution (V/F), and absorption
rate constant (ka). Given the lack of absorption phase samples, ka
was ﬁxed to a literature value (0.6h-1).14 Interindividual (IIV)
and interoccasion variability (IOV) were estimated on CL/F and
residual error described by a proportional model.
Following univariate analysis, CYP2B6 516G>T, CYP2B6
983T>C, and CYP2B6 15582C>T genotypes were signiﬁcantly
associated with CL/F (Supplementary Table 1). Weight and
fat-free mass (FFM) on CL/F and V/F produced a signiﬁcant
drop in objective function value (OFV); however, the change was
greater for weight (DOFV –67.7 vs. –44.0). Ethnicity (Asian and
African separately vs. Caucasian and Hispanic combined; CL/F
decreased by 5% in Hispanics compared to Caucasians and
combining in the model did not affect OFV) and sex on CL/F
were also signiﬁcant. Neither NR1I3 nor CYP3A4*22 single
nucleotide polymorphisms (SNPs) improved model ﬁt (Supple-
mentary Table 1).
For multivariate analysis, inclusion of weight and CYP2B6
983T>C with CYP2B6 516G>T on CL/F was signiﬁcant, but
addition of ethnicity was not. Addition of CYP2A6*9B/
CYP2A6*17 composite genotype consisting of wildtype (CC/
CC) and carriers for either SNP or both (CC/CT or TT, CA
or AA/CC, CA or AA/CT or TT; combined as such due to
lower numbers for the variants) to CYP2B6 516G>T/
983C>T composite genotype (GG/TT, GG/TC or CC, GT/
TT, GT/TC or CC, TT/TT) produced a greater change in
OFV than addition of CYP2B6 15582C>T, so was added into
Table 1 Clinical characteristics and demographics of patients
included in the model (n 5 606)
Parameter Median (range)a
Female (n (%)) 191 (32)
Age (years) 35 (18–69)
Weight (kg) 65 (39–148)
Height (m) 1.68 (1.44–1.90)
BMI (kg/m2) 23 (15–50)
FFM (kg) 87 (41–206)
CrCL (ml/min) 113 (54–264)
CD41 T cell count (cells/mm3) 270 (40–679)
HIV-RNA at week 0 (copies/mL) 56803 (162–10000000)
HIV-RNA <200 copies/mL
at 48 weeksb (n (%))
577 (97)
Randomised dose (n (%))
400 mg efavirenz once daily 311 (51)
600 mg efavirenz once daily 295 (49)
Ethnicity (n (%))
Aboriginal and Torres
Strait Islander (ATSI)
1 (0.2)
African 226 (37)
Asian 201 (33)
Caucasian 76 (13)
Hispanic 102 (17)
CYP2B6 516G>Tc (n (%))
GG 253 (44)
GT 262 (46)
TT 59 (10)
CYP2B6 983T>Cc (n (%))
TT 535 (93)
TC 36 (6.0)
CC 3 (0.5)
CYP2B6 15582C>Td (n (%))
CC 320 (56)
CT 222 (39)
TT 31 (5.0)
CYP2A6 *9Be (n (%))
CC 466 (82)
CA 90 (16)
AA 14 (3.0)
CYP2A6 *17f (n (%))
CC 514 (90)
CT 55 (10)
Table 1 Continued in next column
Table 1 Continued
Parameter Median (range)a
TT 3 (0.5)
CYP3A4 *22d (n (%))
GG 545 (95)
GA 28 (5.0)
AA 0 (0.0)
NR1I3 540C>Tc (n (%))
CC 285 (50)
CT 205 (36)
TT 84 (15)
NR1I3 1089T>Cc (n (%))
TT 153 (27)
TC 277 (48)
CC 144 (25)
BMI: body mass index; FFM: fat free mass; CrCL: creatinine clearance.
aUnless stated otherwise. bn 5 593 available viral load measurements at week 48
(13/606 missing). cn 5 574; dn 5 573; en 5 570; fn 5 572.
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the model ﬁrst. Addition of CYP2B6 15582C>T and sex did
not improve the ﬁt. Following backwards elimination, CYP2B6
516G>T/983T>C/CYP2A6*9B/*17 on CL/F and weight on
CL/F and V/F were retained. For the composite genotype,
those wildtype for both CYP2B6 SNPs with combinations of
CYP2A6*9B/*17 were used as the reference genotype due to no
change in CL/F between groups and given that the impact of
CYP2A6 is more prominent in those without fully functional
CYP2B614 (GG/TT/CC/CC, GG/TT/CC/CT or TT, GG/
TT/CA or AA/CC, GG/TT/CA or AA/CT or TT); this did
not signiﬁcantly affect estimates. Overall, there were 16 geno-
type groups (Supplementary Table 1). IIV CL/F was decreased
15% by the addition of covariates, with the reduction largely
from inclusion of CYP2B6 516G>T (#9.5%) and CYP2B6
983T>C (#3.5%). Grouping patients as extensive, intermediate,
or slow metabolizers (see Methods) after the ﬁnal model was
obtained or as a ﬁnal step of the modeling process did not inﬂu-
ence the individual parameter estimates.
Final model parameters and diagnostic plots are shown (Sup-
plementary Table 2 and Supplementary Figure 1, respectively).
Compared to reference genotypes (11.9 L/h), efavirenz CL/F
decreased by 4.5%–82%, depending on genotype group with typi-
cal population CL/F between 2.2 and 11.4 L/h for an individual
weighing 70 kg (Supplementary Table 2).
Based on 1,000 simulated patients (51% EFV400) with the
same distribution of bodyweights and CYP2B6/CYP2A6 geno-
types as the original dataset and three sampling occasions per
patient, 90% of observed concentrations were within the predic-
tion interval. Stratiﬁed for dose, 90% and 91% of concentrations
were within the prediction interval for EFV400 and EFV600,
respectively, indicative of an adequate model (Supplementary
Figure 2).
Secondary PK parameters
Efavirenz area under the concentration–time curve over 24 hours
(AUC0-24), maximum concentration (Cmax), trough concentra-
tion 24 hours postdose (C24), and concentration 12 hours post-
dose representing the mid-dose interval concentration (C12) were
signiﬁcantly lower for EFV400 (Table 2). PK parameters are
summarized, stratiﬁed by dose and metabolizer status (extensive,
intermediate, and slow; Table 3). The proportion of patients
with C12 below the recommended minimum effective concentra-
tion (MEC) of 10 mg/L12 for each group was similar between
doses (P 5 0.09, 1.00, 1.00, respectively; Fisher’s Exact test);
moreover, the number of patients with C12<MEC was low (n 5
20). There was overlap in concentrations between groups but
generally followed the trend of slow > intermediate > extensive
(Figure 3).
PK-PD analysis
At screening, 231 patients had pVL >100,000 copies/mL and
375 had pVL 100,000 copies/mL. At 48 weeks, 2% (n 5 13)
were missing and 577/593 patients (97%; 97% EFV400, 98%
EFV600) had pVL <200 copies/mL and 3% (n 5 16) had pVL
200 copies/mL.
Following univariate analysis, no categorical variables (dose,
composite genotype, individual SNPs, screening pVL strata) were
found to have signiﬁcant relationships with pVL <200 copies/
mL at 48 weeks (Supplementary Table 3). Following univariate
logistic regression of PK parameters, mean individual predicted
efavirenz logCL/F (odds ratio (OR) (95% CI): 0.037 (0.005–
0.303), P 5 0.002), logAUC0–24 (OR (95% CI): 17.56 (1.61–
192.95), P 5 0.019), logC24 (OR (95% CI): 7.53 (2.04–27.75),
P 5 0.002), and logC12 (OR (95% CI): 21.01 (2.94-150.11),
P 5 0.002) were associated with pVL <200 copies/mL at 48
weeks, although conﬁdence intervals (CIs) were generally wide.
Proportions of patients with pVL 200 copies/mL at 48
weeks stratiﬁed by metabolizer status was similar between doses
(P 5 0.604, 0.172, 1.00, respectively; Fisher’s Exact test, Table 3;
Figure 3).
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Figure 2 Efavirenz concentrations on a log-linear scale following 400 mg
once daily (gray), 600 mg once daily (white), and 800 mg once daily (black)
dosing (n 5 1,491 concentrations; n 5 606 patients). Black lines connect
the points of the full pharmacokinetic profiles of those patients with inten-
sive sampling included in the pharmacokinetic substudy (n 5 46
patients).
Table 2 Geometric mean (90% CI) of mean individual predicted PK parameters for 400 mg and 600 mg efavirenz
Parameter 400 mg EFV 600 mg EFV GMR (90% CI)a
AUC0-24 (mgh/L) 49.2 (47.0–51.5) 67.2 (63.8–70.9) 0.73 (0.68–0.78)
Cmax (mg/L) 2.52 (2.42–2.62) 3.66 (3.51–3.81) 0.69 (0.65–0.73)
C24 (mg/L) 1.40 (1.32–1.49) 1.82 (1.68–1.97) 0.77 (0.70–0.85)
C12 (mg/L) 2.10 (2.01–2.20) 2.85 (2.70–3.0) 0.74 (0.69–0.79)
Differences in parameters were assessed by geometric mean ratios (GMR) and 90% CI (n 5 605).
aEfavirenz 400 mg/efavirenz 600 mg. EFV, efavirenz; CI, confidence interval; AUC0-24, area under the concentration-time curve over 24 hour interval; Cmax, maximum con-
centration; C24, trough concentration, 24 hours postdose; C12, concentration 12 hours postdose representing the mid-dose interval.
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Of 14 and six patients with C12<MEC for EFV400 and
EFV600, one and three had pVL 200 copies/mL at 48 weeks,
respectively (Figure 3). Composite CYP2B6 516G>T/983T>C/
CYP2A6*9B/*17 genotype was TT/TT/CC/CC (slow), GG/TT/
CC/CC (extensive), GT/TT/CC/CC (intermediate), and GG/
TC or CC/CA or AA/CC (slow), respectively, for these four
patients. The ranges of C12 stratiﬁed by metabolizer status of the
nine (EFV400) and seven patients (EFV600) with pVL 200
copies/mL at 48 weeks (n 5 16 total) were: EFV400: 1.31 mg/L
(extensive, n 5 1), 1.45–2.90 mg/L (intermediate, n 5 6),
0.85 mg/L and 2.99 mg/L (slow, n 5 2); EFV600: 0.12 mg/L and
1.60 mg/L (extensive, n 5 2), 0.37 mg/L and 3.02 mg/L (interme-
diate, n 5 2), 0.68 mg/L and 8.15 mg/L (slow, n 5 2), and
6.24 mg/L (missing, n5 1).
Treatment discontinuation and adverse events
Overall, 42/606 (7%) discontinued therapy during the 48 weeks
(median (range) 15 weeks (0.1–49)). Seven percent had severe
adverse events and 65% and 48% experienced efavirenz-related
and CNS adverse events, respectively. Signiﬁcantly more patients
administered EFV600 had efavirenz-related (70% vs. 61%; P 5
0.017) and CNS events (52% vs. 44%; P 5 0.042), compared to
EFV400 (Pearson’s chi-square).
Predicted PK parameters were not signiﬁcantly different
between those who did and did not discontinue efavirenz or had
adverse events (Table 4). After adjusting for age, sex, and dose
and stratifying by country, those with CYP2B6 516TT and
CYP2A6*9B heterozygote or homozygous variant allele (CA or
AA) were at increased risk of discontinuation (HR (95% CI):
2.81 (1.12–7.06); P 5 0.028 and 2.14 (1.05–4.35); P 5 0.035,
respectively). EFV600 was independently associated with 24%
increased risk of efavirenz-related side effects when adjusted for
age and sex and stratiﬁed by country (HR (95% CI): 1.24 (1.01–
1.53); P5 0.039).
DISCUSSION
Efavirenz dose was not associated with virological response at 48
weeks despite signiﬁcantly lower exposure with EFV400. Pre-
dicted C12 was <1.0 mg/L (suggested MEC
12) in 5% (n 5 14)
and 2% (n 5 6) for EFV400 and EFV600, respectively, following
4–12 weeks of therapy. Of these patients, only one EFV400 and
three EFV600 patients had detectable pVL at 48 weeks.
C12<1·0mg/L (n) 10 2 2 0 3 1 2 0
VL≥200copies/mL (n) 1 6 2 0 2 2 2 1
Missing VL (n) 2 2 2 0 2 0 3 2
C12<1·0mg/L
&
VL≥200copies/mL (n)
0 0 1 0 1 1 1 0
Extensive Intermediate Slow Missing Extensive Intermediate Slow Missing
0.01
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Figure 3 Mean individual predicted efavirenz concentrations at 12 hours postdose (C12) on a log scale stratified for metabolizer status (extensive, inter-
mediate, slow) and dose (400 and 600 mg once daily; n 5 295 and n 5 273, respectively). The black dashed line illustrates the recommended minimum
effective concentration for efavirenz (MEC) of 1.0 mg/L. Each point represents an individual patient and the solid black line the median concentrations.
Numbers of patients with C12 below the MEC or with detectable or missing viral load at 48 weeks are shown. C12: concentration 12 hours post-dose
representing the mid-dose interval concentration; VL: viral load.
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Moreover, patients randomized to EFV400 experienced signiﬁ-
cantly fewer efavirenz-related adverse events.
The impact of CYP2B6 516G>T and 983T>C on efavirenz
PK have been well documented in different populations8–10,13,15
and replicated in ENCORE1. CYP2A6 polymorphisms including
CYP2A6*9B and/or *17 carriers8,16 have been associated with
higher efavirenz concentrations, particularly in those with
impaired CYP2B6 function. Composite CYP2B6
516G>T/983T>C/CYP2A6*9B/*17 genotype and bodyweight
were signiﬁcantly associated with efavirenz CL/F in ENCORE1.
The model described the data well and parameters were within
reported ranges.9,14,15 Addition of covariates reduced CL/F vari-
ability by 15%. The patient population was diverse and although
58% of variability remained unexplained (37% and 21%; IIV and
IOV, respectively), it could be attributed to covariates not cap-
tured in the study, e.g., unidentiﬁed host genetic factors and
potentially variable adherence.
Lower efavirenz concentrations have been associated with
NR1I3 540C>T and NR1I3 1089T>C carriers (TT, CC,
respectively).7,17,18 Relationships between NRII3 540C>T or
1089T>C and CL/F was not conﬁrmed in ENCORE1 patients.
The impact of CYP2B6 15582C>T SNP on efavirenz C24 in
combination with CYP2B6 516G>T and 983T>C was recently
described.19 Patients wildtype for all three SNPs (CYP2B6
15582CC/516GG/983TT) had the lowest median efavirenz
C24, potentially placing them at risk of virological failure. Despite
CYP2B6 15582C>T not meeting statistical criteria to remain in
the ENCORE1 population PK model, post-hoc analysis was per-
formed to estimate each patient’s C24 based on CYP2B6
15582C>T/516G>T/983T>C composite genotype as previ-
ously described.19 Patients wildtype for all three SNPs had the
lowest model-predicted median C24 and concentrations were
lower for EFV400. No patients with this genotype had
pVL200 copies/mL at 48 weeks (Supplementary Figure 3).
Given the small number of patients with pVL 200 copies/mL,
interpretation of this observation is limited.
Dose was not associated with pVL <200 copies/mL at 48
weeks, despite lower concentrations with EFV400. No relation-
ships between genetic polymorphisms and viral suppression were
observed. Patients were at higher risk of suppressing virus in asso-
ciation with increasing AUC0-24, C24, and C12, although the CIs
were generally wide. Due to low numbers of detectable viral loads
at 48 weeks, the models should be interpreted with caution.
A therapeutic range (1.0–4.0 mg/L) proposed in 2001 by Mar-
zolini et al. (n 5 130 HIV-infected patients of unreported eth-
nicity) was adopted for efavirenz threshold concentrations.
Seventy-six percent suppressed virus below 400 copies/mL; of
those who failed therapy, 50% had a mid-dose interval concentra-
tion <1.0 mg/L.12 Efavirenz cutoffs have not been reevaluated in
a large, randomized, controlled trial, particularly in combination
with more active therapies such as tenofovir and emtricitabine.
ENCORE1 data strongly indicate that this putative MEC does
not represent the efﬁcacy cutoff for current efavirenz-based regi-
mens. Indeed, of 16 patients with pVL 200 copies/mL at 48
weeks (nine vs. seven for EFV400 and EFV600, respectively),
only one and three individuals had predicted C12 <1.0 mg/L.
Furthermore, Ugandan patients (n 5 99) receiving efavirenz
with zidovudine/lamivudine also experienced a low number of
failures (n 5 6; pVL 40 copies/mL) that were not associated
with plasma exposure.20
Limited failures in ENCORE1 meant robust reassessment of
the 1.0 mg/L cutoff was not feasible; however, these data ques-
tion the validity of this MEC. Self-reported adherence was
recorded at weeks 4 and 48, and although the impact of adher-
ence on clinical outcome cannot be assessed, patients with detect-
able viral load at 48 weeks (n 5 16) reported taking all or most
of their medications (except therapy discontinuations) including
four patients with C12 <1.0 mg/L.
Efavirenz therapy is associated with early neuropsychiatric
adverse events in over half of patients21,22 that generally subside
with time. Although relationships between CNS toxicity and efa-
virenz plasma concentrations have been observed,11,12,23,24 no
association was seen in ENCORE1. Despite this, the incidence of
efavirenz-related and CNS adverse events was lower with
EFV400. Furthermore, EFV600 was associated with higher risk
of efavirenz-related adverse effects. Efavirenz and its 8-hydroxy
(8OH) metabolite produced damage in rat neuronal cultures in
vitro, with 8OH-efavirenz exhibiting toxicity 10-fold higher than
the parent drug.25 Although translating in vitro observations to
clinical settings is difﬁcult, these data suggest that patients with
higher 8OH-efavirenz CNS concentrations (e.g., extensive
metabolizers) could be more susceptible to CNS toxicities.21
Alternatively, those without fully functional CYP2B6 could be at
lower risk. In ENCORE1, CYP2B6 983T>C carriers (TC or
CC) had 33% lower risk of CNS side effects compared to wild-
type (TT), suggesting lower 8OH-efavirenz formation and
Table 4 Differences in mean individual predicted PK parameters for toxicity endpoints, assessed by calculation of geometric mean
ratios (GMR) and 90% CI (n 5 606).
GMR (90% CI)a
Parameter Discontinuation Efavirenz-related adverse event Serious adverse event CNS adverse event
AUC0-24 0.90 (0.78–1.04) 0.95 (0.88–1.02) 0.97 (0.84–1.12) 0.97 (0.90–1.05)
Cmax 0.88 (0.78–1.00) 0.93 (0.87–1.00) 0.99 (0.87–1.12) 0.96 (0.90–1.02)
C24 0.94 (0.77–1.14) 0.96 (0.87–1.07) 0.93 (0.76–1.14) 1.00 (0.90–1.10)
C12 0.90 (0.78–1.05) 0.95 (0.88–1.03) 0.96 (0.83–1.12) 0.98 (0.91–1.05)
aDid not have the event/had the event. CI, confidence interval; AUC0-24, area under the concentration-time curve over 24-hour interval; Cmax, maximum concentration;
C24, trough concentration, 24 hours postdose; C12, concentration 12 hours postdose representing the mid-dose interval.
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CYP2B6 15582CT/TT had a higher risk (53%) (Supplemen-
tary Table 4).
Another ENCORE1 substudy (n 5 28) found concentrations
of efavirenz and its metabolites were slightly lower in plasma and
CSF for EFV400 and exposure within the two compartments
were correlated and associated with CYP2B6 516G>T geno-
type.26 Conversely, no relationships were observed between dose,
plasma efavirenz, or 8OH-efavirenz or genotype with CSF 8OH-
efavirenz. Although the CSF substudy was small and exploratory,
a potential connection was noted between CSF 8OH-efavirenz
and patient-reported CNS symptoms by questionnaire26 and
most individuals achieved CSF 8OH-efavirenz concentrations
greater than those responsible for neuronal damage in rat cul-
tures.25,26 ENCORE1 contributes signiﬁcantly to our under-
standing of efavirenz-induced toxicity, although the mechanisms
remain to be fully elucidated.
Efavirenz discontinuation in ENCORE1 occurred at a rate
consistent with previous reports.27–29 Possession of CYP2B6
516G>T homozygous variant (TT) and CYP2A6*9B heterozy-
gous or homozygous variant alleles (CA or AA) but not dose
were associated with higher risk of discontinuation. The relation-
ship observed with CYP2B6 516TT agrees with Wyen et al.,
who evaluated risk factors for early discontinuation (<3
months).29 Increased risk was also reported in patients with
NR1I3 540CC; this was not seen in ENCORE1. EFV400 dis-
continuation was not associated with genotypes when analyzed
separately (Supplementary Table 5).
Pharmacogenetic testing has been suggested to aid efavirenz
dose optimization.30,31 Genetic risk scores were used to predict
early efavirenz discontinuation; individuals scoring 6 (CYP2B6
homozygous loss of function and loss of function in an accessory
metabolic pathway of CYP2A6 or CYP3A4) had a higher risk of
discontinuation compared to those with lower scores.32 Although
statistically signiﬁcant and partially conﬁrmed in ENCORE1, the
number of patients scoring 6 was small (13/272),32 thus
questioning the feasibility of translating this approach into a
cost-effective, population-wide clinical tool, particularly in
resource-limited settings. The data presented here indicate that
pharmacogenetic analysis of known alleles is no more useful at
predicting outcome, such as efﬁcacy or discontinuation, for the
efavirenz doses assessed (400 mg and 600 mg).
The antitubercular agent rifampicin is a cytochrome P450
enzyme inducer, markedly lowering concentrations of some anti-
retrovirals, potentially jeopardizing virological success.33 Coadmi-
nistration with efavirenz has generated conﬂicting data and a
systematic review reported a time-dependent interaction between
rifampicin and efavirenz,34 with efavirenz concentrations
decreased in individuals receiving a single dose or 8 days of
therapy, while PK parameters increased in those established on
efavirenz.34 Furthermore, the STRIDE study observed good viro-
logical control in coinfected patients on and off TB therapy
including rifampicin.35 Further PK-PD studies of efavirenz and
rifampicin in coinfected populations are warranted.
Current WHO guidelines recommend efavirenz as ﬁrst-line
treatment during pregnancy3,36; PK-PD data of efavirenz during
pregnancy and postpartum are sparse. A recent review concluded
that pregnancy had little clinical impact on efavirenz PK, with
good rates of viral suppression achieved in mothers at delivery.37
However, others observed higher efavirenz CL/F and lower
AUC0-24 and Cmin during pregnancy compared to postpartum.
38
When stratiﬁed by CYP2B6 516G>T, PK changes were mark-
edly greater in wildtype patients (516GG). Impact on clinical
outcome requires investigation.38 Speculatively, these ﬁndings
together with ENCORE1 outcomes suggest scope for dose reduc-
tion to 400 mg in HIV/TB coinfected and potentially pregnant
patients. Transition to new recommendations would require
careful prospective monitoring.
Although plasma efavirenz concentrations were reduced with
EFV400 compared to EFV600, virus suppression was similar.
Fewer adverse events with the reduced dose may improve quality
of life. Genetic polymorphisms were associated with treatment
discontinuation but the biological importance is uncertain. Fur-
thermore, genetic testing is unlikely to be widely implemented,
particularly in resource-limited settings and would be no more
useful for EFV400 than EFV600. Antiretroviral costs pose a bar-
rier to rollout of treatment to meet WHO targets. Reducing efa-
virenz dose to 400 mg could provide an economically viable
solution, cutting costs and expanding access while maintaining
good efﬁcacy and reducing adverse events.
METHODS
Patients
ENCORE1 has been described.5 Brieﬂy, HIV-infected individuals 16
years with pVL 1,000 copies/mL and CD4 cell counts between 50–
500 cells/mm3 without preexisting CDC AIDS-deﬁning illnesses or
active opportunistic infections and no prior exposure to antiretrovirals
were eligible to participate in this randomized, double-blind, placebo-
controlled trial. Patients were recruited from 13 countries (38 sites)
across Africa, Asia, South America, Europe, and Oceania; ethical and
regulatory approval and written informed consent were obtained.5
Patients were randomized to receive daily EFV400 or EFV600 in combi-
nation with tenofovir/emtricitabine (Truvada, 300/200 mg once daily).
After randomization, patients requiring treatment with rifampicin for
TB were switched to open-label efavirenz 600 mg (or 800 mg) once
daily, then returned to randomized efavirenz on completion of
rifampicin.
Random, single blood samples were drawn from all patients at
weeks 4 and 12 (between 8–16 hours postdose). Intensive sampling was
also undertaken in a subgroup (from Argentina, South Africa, Thailand,
United Kingdom) between weeks 4 and 8 at predose (0 hour), 2, 4, 8,
12, 16, and 24 hours postdose. Plasma efavirenz concentrations were
determined by a fully validated high-performance liquid chromatography
tandem mass spectrometry (HPLC-MS/MS) method with LLQ and
upper limit of quantiﬁcation (ULQ) of 0.025 and l0.0 mg/L,
respectively.39
Genotyping
Total genomic DNA was extracted from patient blood using the QI
Amp DNA mini kit (Qiagen, West Sussex, UK) according to the manu-
facturer’s instructions. Samples were quantiﬁed and normalized to 20
ng/lL. Genotyping for SNPs previously associated with efavirenz PK
(CYP2B6 516 G>T (rs3745274),8,9,13,15 CYP2B6 983 T>C
(rs28399499),10 CYP2B6 15582C>T (rs4803419),19 CYP2A6*9B
(rs8192726),8 CYP2A6*17 (rs28399454),8 CYP3A4*22 (rs35599367),40
NR1I3 (CAR) 540C>T (rs2307424)7 and NR1I3 1089T>C
(rs3003596)18) was performed using real-time polymerase chain reaction
(PCR) allelic discrimination assays (C_7817765_60, C_60732328_20,
C_7817764_10, C_29560333_20, C_34816076_20, C_59013445_10,
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C_25746794_20, and C_16194070_10, respectively; Applied Biosys-
tems, Foster City, CA) as previously described.17,40
PK modeling
Nonlinear mixed effects modeling (NONMEM v. 7.2, ICON Develop-
ment Solutions, Ellicott City, MD) was applied to the data41 with initial
parameter estimates taken from the literature.9,14,42
Covariates including age, weight, FFM, body mass index (BMI), sex,
ethnicity, concomitant rifampicin, and CYP2B6 516G>T, CYP2B6
983T>C, CYP2B6 15582C>T, CYP2A6*9B, CYP2A6*17,
CYP3A4*22, NR1I3 540C>T, and NR1I3 1089T>C genotypes on efa-
virenz CL/F were explored. Covariates were initially assessed (univari-
ate), with the exception of CYP2A6*9B and CYP2A6*17, which were
tested in combination with CYP2B6 SNPs due to more prominent
effects observed in those without fully functional CYP2B6.14
Model ﬁt was assessed by statistical and graphical methods. Decreased
minimal OFV by at least 3.84 units was required to accept a model with
one extra parameter (P 5 0.05, v2 distribution, 1 d.f.). Once signiﬁcant
covariates were included a backwards elimination process was performed
and biologically plausible covariates producing an increase in OFV of at
least 10.83 units (P 5 0.001, v2 distribution, 1 d.f.) were retained.
Model evaluation was performed by simulation and visual predictive
check. Using model estimates a 90% prediction interval (P5-P95) was
generated from 1,000 simulated patients with the same distribution of
doses and signiﬁcant covariates as the original dataset; observed data
were superimposed. Inclusion of 90% of data points within the predic-
tion interval indicated an adequate model.
Secondary PK parameters
Along with model-deﬁned parameters, secondary PK parameters were
estimated for each patient at each sampling occasion using the ﬁnal
model: AUC0-24, Cmax, C24, and C12. If patients had more than one
sampling occasion, the mean of individual predicted PK parameters were
determined and carried forward into the analyses outlined below.
Differences between doses for efavirenz AUC0-24, Cmax, C24, and C12,
were evaluated by geometric mean ratios (GMR) and 90% CI using log-
transformed data then expressed as linear values. Differences were con-
sidered signiﬁcant if the 90% CI did not include 1.
Genotypes were distributed into three groups based on change in efa-
virenz CL/F and CYP2B6/CYP2A6 alleles:
1. Extensive metabolizers: homozygous wildtype for CYP2B6 SNPs with
combinations of CYP2A6 alleles (GG/TT/CC/CC, GG/TT/CC/
CT or TT, GG/TT/CA or AA/CC, GG/TT/CA or AA/CT or
TT).
2. Intermediate metabolizers: homozygous wildtype CYP2B6 516G>T
and combinations of CYP2A6 alleles with heterozygous or homozy-
gous variant CYP2B6 983T>C or heterozygous variant CYP2B6
516G>T with CYP2B6 983T>C homozygous wildtype and combi-
nations of CYP2A6 alleles (GG/TC or CC/CC/CC, GT/TT/CC/
CC, GT/TT/CC/CT or TT, GT/TT/CA or AA/CC, GT/TT/CA
or AA/CT).
3. Slow metabolizers: heterozygous variant CYP2B6 516G>T with het-
erozygous or homozygous variant CYP2B6 983T>C, or homozygous
variant CYP2B6 516G>T with homozygous wildtype CYP2B6
983T>C with combinations of CYP2A6 alleles (GG/TC or CC/
CC/CT or TT, GG/TC or CC/CA or AA/CC, GG/TC or CC/
CA or AA/CT, GT/TC or CC/CC/CC, GT/TC or CC/CC/CT
or TT, GT/TC or CC/CA or AA/CC, TT/TT/CC/CC, TT/TT/
CC/CT or TT, TT/TT/CA or AA/CC, TT/TT/CA or AA/CT).
Proportions of patients with C12 below the recommended MEC of
1.0 mg/L12 were determined for each group.
PK-PD analysis
The primary PD endpoint was proportion of patients with
pVL <200 copies/mL at 48 weeks by randomized dose. Patients with-
out a recorded viral load were excluded. Logistic regression was per-
formed to assess associations between pVL <200 copies/mL at 48
weeks and mean individual predicted logCL/F, logAUC0-24, logCmax,
logC24, and logC12. Univariate analyses (Fisher’s Exact test or Pear-
son’s chi-square, as appropriate) were carried out for dose, SNPs, and
screening pVL />100,000 copies/mL.
Treatment discontinuation and adverse events
Discontinuation was deﬁned as interruption in efavirenz >30 days.
Efavirenz-related adverse events and CNS-related side effects (including
abnormal dreams, anxiety, cerebellar disorder and ataxia, dizziness, head-
ache and migraine, impaired concentration, insomnia, seizure, and som-
nolence) were categorized as those deﬁned in the Sustiva Prescribing
Information.27
Comparison of PK parameters between those who did or did not stop
therapy and experience adverse events was performed by GMR (90%
CI). Differences in proportions of each endpoint by efavirenz dose were
assessed by Fisher’s Exact test or Pearson’s chi-square. Evaluation of rela-
tionships between efavirenz discontinuation and adverse events with
dose and SNPs was performed by Cox regression adjusted a priori for
potential confounders (age, sex). Post-hoc exploratory analysis of the
crude association of PK parameters and CNS-related side effects (as a
subset of adverse events) was undertaken using logistic regression.
Statistical analyses were performed using SPSS (v. 21, IBM, Armonk,
NY).
Additional Supporting Information may be found in the online version of
this article.
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